INFORMATION DISCLOSURE CITATION				1	Attorney Docket No.: 2503-1169]	Application No	ONAL	-
IN AN APPLICATION					Applicant: 10/5				4
(Use several sheets if necessary)					Filing Date: September 2, 2005	(Group Art Unit: 1641		
		U	J.S. PATI	ENT	DOCUMENTS				
Initial			Date		Name	Class	Subclass Filing da (if appropri		
/JLG/	5,770,421	6/23/1998		MORRIS ET AL.					
Examiner	DA No	F			NT DOCUMENTS	Clas		<u> </u>	
Initial	Document Number		Date		Country		Subclass	Yes	slatio
/JLG/	WO 95/02187		1/19/1995		WIPO			103	1
/JLG/	WO 95/14930		6/1/1995		WIPO		-		
/JLG/	WO 98/49317		11/5/1998		WIPO				
	OTHER DOCUM	ENTS	 (Including	Aut	hor, Title, Date, Pertinent	Pages. I	 Etc.)		
/JLG/	DATABASE WPI Section Ch, Week 199325 Derwent Publications Ltd., London, GB; Class A96, AN 1993-201126 XP002249142 & JP 05 126833 A (TOSOH CORP) 21 May 1993 (1993-05-21) abstract								
/JLG/	SADICK M D ET AL: "Kinase receptor activation (KIRA): A rapid and accurate alternative to end-point bioassays" JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 1999 NETHERLANDS, vol. 19, no. 6, 1999, pages 883-891, XP002249139 ISSN: 0731-7085 the whole document								
/JLG/	TURTURRO FRANCESCO ET AL: "Model of inhibition of the NPM-ALK kinase activity by herbimycin A." CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, UNITED STATES JAN 2002, vol. 8, no. 1, January 2002 (2002-01), ISSN: 1078-0432 the whole document								
/JLG/	MORRIS STEPHAN W ET lymphoma, encodes a nove kinase (LTK)." ONCOGENI whole document	el neur	al receptor	tyros	sine kinase that is highly rel	ated to I	eukocyte ty	rosine	
EXAME:	rn.			T-=	ATT 0011017				
EXAMIN	/James L. Grun/			1 0/	ATE CONSIDERED 03/1	8/2009			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* English language abstract provided for the Examiner's convenience

BC/gw